MedinCell Future Growth
Future criteria checks 5/6
MedinCell is forecast to grow earnings and revenue by 67.8% and 40.5% per annum respectively while EPS is expected to grow by 68.7% per annum.
Key information
67.8%
Earnings growth rate
68.7%
EPS growth rate
Pharmaceuticals earnings growth | 20.6% |
Revenue growth rate | 40.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 112 | 48 | N/A | 46 | 1 |
3/31/2026 | 51 | 16 | 12 | 14 | 4 |
3/31/2025 | 42 | 1 | -6 | -1 | 5 |
3/31/2024 | 14 | -24 | -26 | -23 | 5 |
9/30/2023 | 14 | -26 | -24 | -23 | N/A |
6/30/2023 | 14 | -29 | -23 | -22 | N/A |
3/31/2023 | 14 | -32 | -22 | -21 | N/A |
12/31/2022 | 13 | -29 | -22 | -21 | N/A |
9/30/2022 | 12 | -27 | -22 | -20 | N/A |
6/30/2022 | 10 | -26 | -23 | -21 | N/A |
3/31/2022 | 8 | -25 | -23 | -21 | N/A |
12/31/2021 | 9 | -22 | -21 | -19 | N/A |
9/30/2021 | 9 | -20 | -18 | -17 | N/A |
6/30/2021 | 9 | -19 | -15 | -14 | N/A |
3/31/2021 | 8 | -19 | -13 | -12 | N/A |
12/31/2020 | 7 | -22 | -12 | -11 | N/A |
9/30/2020 | 5 | -26 | -11 | -10 | N/A |
6/30/2020 | 6 | -25 | -12 | -11 | N/A |
3/31/2020 | 6 | -24 | -13 | -13 | N/A |
12/31/2019 | 6 | -21 | -16 | -16 | N/A |
9/30/2019 | 6 | -19 | -19 | -19 | N/A |
6/30/2019 | 5 | -19 | -18 | -17 | N/A |
3/31/2019 | 4 | -20 | -17 | -16 | N/A |
12/31/2018 | 6 | -17 | -12 | -11 | N/A |
9/30/2018 | 7 | -15 | -8 | -7 | N/A |
6/30/2018 | 8 | -12 | -7 | -6 | N/A |
3/31/2018 | 8 | -10 | -7 | -5 | N/A |
3/31/2017 | 10 | -4 | N/A | -3 | N/A |
3/31/2016 | 9 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: MEB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEB is expected to become profitable in the next 3 years.
Revenue vs Market: MEB's revenue (40.5% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: MEB's revenue (40.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MEB's Return on Equity is forecast to be high in 3 years time